table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

Background: Routine human papillomavirus (HPV) immunization in Belgium is currently regionally managed, with school-aged girls receiving the 9-valent HPV (9vHPV) vaccine in Flanders and Wallonia-Brussels with a national catch-up program for females only. This study will assess whether expanding these programs to gender-neutral vaccination (GNV) with the 9vHPV vaccine is a cost-effective strategy in Belgium. Methods: A validated HPV-type transmission dynamic model estimated the potential health and economic impact of regional vaccination programs, comparing GNV versus female-only vaccination (F... Mehr ...

Verfasser: Steven Simoens (587068)
Andre Bento-Abreu (10583999)
Barbara Merckx (10584002)
Sophie Joubert (10584005)
Steve Vermeersch (10584008)
Andrew Pavelyev (10131585)
Stefan Varga (9770121)
Edith Morais (10584011)
Dokumenttyp: Dataset
Erscheinungsdatum: 2021
Schlagwörter: Pharmacology / Basic Pharmacology / Clinical Pharmacology and Therapeutics / Clinical Pharmacy and Pharmacy Practice / Pharmaceutical Sciences / Pharmacogenomics / Toxicology (incl. Clinical Toxicology) / Pharmacology and Pharmaceutical Sciences not elsewhere classified / HPV / human papillomavirus / vaccine / cervical cancer / genital warts / cost-effectiveness / Belgium / 9-valent
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-27365664
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.3389/fphar.2021.628434.s001